1. Cathomas G. Human herpes virus 8: a new virus discloses its face. Virchows Arch. 2000;436:195-206.
2. Chang Y, Cesarman CE, Pessin MS, et al. Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi’s sarcoma. Science . 1994;266:1865-1869.
3. Tur E, Brenner S. Treatment of Kaposi’s sarcoma. Arch Dermatol. 1996;132:327-331.
4. Gorsky M, Epstein JB. A case series of acquired immunodeficiency syndrome patients with initial neoplastic diagnoses of intraoral Kaposi’s sarcoma. Oral Surg Oral Med Oral Pathol Oral Radiol Endod . 2000;90:612-617.
5. Chaplin DJ. The effect of therapy on tumor vascular function. Int J Radiat Biol. 1991;60:311-325.
6. Donehower RC, Rowinsky EK. Anticancer drugs derived from plants. In: De Vita VT, Hellman S, Rosenberg SA, eds. Cancer: Principles and Practice of Oncology. 4th ed. Philadelphia, PA: Lippincott; 1993:409-417.
7. Epstein JB. Treatment of oral Kaposi’s sarcoma with intralesional vinblastine. Cancer. 1993;71:1722-1725.
8. McCormick SU. Intralesional vinblastine injections for the treatment of oral Kaposi’s sarcoma: report of 10 patients with 2-year follow-up. J Oral Maxillofac S urg. 1996;54:583-587.
9. Schwartz RA, Micali G, Nasca MR, et al. Kaposi sarcoma: a continuing conundrum. J Am Acad Dermatol. 2008;59:179-206.
10. Schwartz RA. Kaposi’s sarcoma: an update. J Surg Oncol. 2004;87:146-151.
11. Laor Y, Schwartz RA. Epidemiologic aspects of American Kaposi’s sarcoma. J Surg Oncol . 1979;12:299-303.
12. Gill K, Shah J. Kaposi sarcoma in patients with diabetes and wounds. Adv Skin Wound Care . 2006;19:196-198, 201.
13. Hurlbut W, Lincoln CS Jr. Multiple hemorrhagic sarcoma and diabetes mellitus; review of a series, with report of two cases. Arch Intern Med (Chi c). 1949;84:738-750.
14. Fischer JW, Cohen DM. Simultaneous occurrence of Kaposi’s sarcoma, leukemia and diabetes mellitus; report of a case. Am J Clin Pathol. 1951;21:586-589.
15. Tankel R. Kaposi’s sarcoma and diabetes mellitus. Arch Dermatol. 1971;104:442-444.
16. Langtry JA, Bottomley DM, Phillips RH, et al. The infra-red coagulator in the treatment of AIDS-related Kaposi’s sarcoma and a comparison with radiotherapy. Clin Exp Dermatol . 1994;19:23-25.
17. Von Roenn JH, Cianfrocca M. Treatment of Kaposi’s sarcoma. Cancer Treat Res. 2001;104:127-148.
18. Dezube BJ. AIDS-related Kaposi sarcoma. the role of local therapy for a systemic disease. Arch Dermatol. 2000;136:1554-1556.
19. Oysul K, Beyzadeoglu M, Surenkok S, et al. A dose-response analysis for classical Kaposi’s sarcoma management by radiotherapy. Saudi Med J. 2008;29:837-840.
20. Morganroth GS. Topical 0.1% alitretinoin gel for classic Kaposi sarcoma. Arch Dermatol. 2002;138:542-543.
21. Rongioletti F, Zaccaria E, Viglizzo G. Failure of topical 0.1% alitretinoin gel for classic Kaposi sarcoma: first European experience. Br J Dermatol. 2006;155:856-857.
22. Klein E, Schwartz RA, Laor Y, et al. Treatment of Kaposi’s sarcoma with vinblastine. Cancer. 1980;45:427-431.
23. Flaitz CM, Nichols CM, Hicks MJ. Role of intralesional vinblastine administration in treatment of intraoral Kaposi’s sarcoma in AIDS. Eur J Cancer B Oral Oncol. 1995;31B:280-285.
24. Epstein JB, Lozada-Nur F, McLeod WA, et al. Oral Kaposi’s sarcoma in acquired immunodeficiency syndrome. review of management and report of the efficacy of intralesional vinblastine. Cancer. 1989;64:2424-2430.
25. Antman K, Chang Y. Kaposi’s sarcoma. N Engl J Med . 2000;342:1027-1038.
26. Ramírez-Amador V, Esquivel-Pedraza L, Lozada-Nur F, et al. Intralesional vinblastine vs. 3% sodium tetradecyl sulfate for the treatment of oral Kaposi’s sarcoma. a double blind, randomized clinical trial. Oral Oncol. 2002;38:460-467.
27. Boudreaux AA, Smith LL, Cosby CD, et al. Intralesional vinblastine for cutaneous Kaposi’s sarcoma associated with acquired immunodeficiency syndrome. a clinical trial to evaluate efficacy and discomfort associated with infection. J Am Acad Dermatol. 1993;28:61-65.
28. Odom RB, Goette DK. Treatment of cutaneous Kaposi’s sarcoma with intralesional vincristine. Arch Dermatol. 1978;114:1693-1694.
29. Tappero JW, Conant MA, Wolfe SF, et al. Kaposi’s sarcoma. epidemiology, pathogenesis, histology, clinical spectrum, staging criteria and therapy. J Am Acad Dermatol . 1993;28:371-395.
30. Smith KJ, Skelton HG, Turiansky G, et al. Hyaluronidase enhances the therapeutic effect of vinblastine in intralesional treatment of Kaposi’s sarcoma. Military Medical Consortium for the Advancement of Retroviral Research (MMCARR). J Am Acad Dermatol . 1997;36(2, pt 1):239-242.
31. Célestin Schartz NE, Chevret S, Paz C, et al. Imiquimod 5% cream for treatment of HIV-negative Kaposi’s sarcoma skin lesions: a phase I to II, open-label trial in 17 patients [published online ahead of print February 20, 2008]. J Am Acad Dermatol . 2008;58:585-591.
32. Poignonec S, Lachiver LD, Lamas G, et al. Intralesional bleomycin for acquired immunodeficiency syndrome-associated cutaneous Kaposi’s sarcoma. Arch Dermatol. 1995;131:228.
